RecruitingNot ApplicableNCT04104529
Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
Establishment of a Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Enrollment
350 participants
Start Date
Oct 28, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
Development of a clinico-biological database allowing the provision of clinical data and corresponding biological materials to the medical and scientific community.
Eligibility
Min Age: 18 Years
Inclusion Criteria8
- Age ≥ at 18 years old,
- Patient treated in the Nuclear Medicine Department for the treatment by metabolic radiotherapy,
- Patient treated as part of his treatment for:
- thyroid cancer,
- a neuroendocrine tumor or
- prostate cancer.
- Patient having accepted the complementary blood sample,
- Patient having given his informed, written and express consent.
Exclusion Criteria5
- Patient not affiliated to a social security scheme,
- Subject under tutelage, curatorship or safeguard of justice,
- Patient in an emergency situation
- Patient whose regular monitoring is a priori impossible for psychological, family, social or geographical reasons,
- Pregnant and / or breastfeeding woman
Interventions
OTHERBiological collection
The biological collection will also include samples of blood samples collected before and during treatment.
OTHERtumor collection
Tumor collection (diagnosis) will be done for thyroid cancer and neuroencrine
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04104529
Related Trials
Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program
NCT0489583916 locations
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT0697084728 locations
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT054354953 locations
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
NCT073986901 location
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT0678067052 locations